SCHEMBL14949252

SCHEMBL14949252

CCOc1cc(Oc2ccc(-c3nnc(Nc4cccc5c4CCCC5)[nH]3)cc2)nc(N)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.35
LMNA P02545 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
EGFR P00533 1/20 0.34
RAB9A P51151 3/20 0.34
ALDH1A1 P00352 3/20 0.34
NPC1 O15118 2/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
ALOX5 P09917 1/20 0.33
CDKN1A P38936 1/20 0.33
MAPT P10636 1/20 0.33
P2RX7 Q99572 1/20 0.32
MEN1 O00255 1/20 0.32
KCNK2 O95069 1/20 0.32
KCNK10 P57789 1/20 0.32
KMT2A Q03164 1/20 0.32
KCNK18 Q7Z418 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CCR4 P51679 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12336256 0.89 MAPT (0.33) DHFRLMNAL3MBTL1EGFRALDH1A1
SCHEMBL14949265 0.85 NUDT1 (0.38) DHFRLMNARAB9AALDH1A1NPC1
SCHEMBL627156 0.82 PDGFRB (0.46) LMNAEGFRALOX5P2RX7MEN1
SCHEMBL12348778 0.80 PDGFRB (0.46) LMNAEGFRALOX5P2RX7MEN1
SCHEMBL14949247 0.79 RAB9A (0.37) EGFRRAB9AALDH1A1NPC1MAPK1
SCHEMBL14949248 0.79 SMN1; SMN2 (0.38) LMNAL3MBTL1RAB9AALDH1A1NPC1
SCHEMBL14949254 0.78 RAB9A (0.38) RAB9AALDH1A1NPC1MAPK1SMN1; SMN2
SCHEMBL12336404 0.77 MEN1 (0.35) LMNAL3MBTL1EGFRALDH1A1SMN1; SMN2
SCHEMBL14949246 0.77 SMN1; SMN2 (0.38) RAB9AALDH1A1NPC1MAPK1SMN1; SMN2
SCHEMBL12336730 0.77 SMN1; SMN2 (0.43) LMNAL3MBTL1EGFRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 DHFR 1841/4885LMNA 3696/4885L3MBTL1 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.